China Approves Commercial Sale of Rare-Disease Narcolepsy Therapy
Auf einen Blick
- China's NMPA has approved a rare-disease therapy for commercial sales to treat narcolepsy type 1 in individuals aged 16 and older.
- The unnamed drug previously received fast-track status in the US and orphan-drug designation in Japan and the EU, indicating international recognition for its importance.
KI-generierte Zusammenfassung
Warum es wichtig ist
The NMPA has approved a rare-disease therapy for narcolepsy type 1 for commercial sales in people aged 16 and older. The drug has previously received fast-track designations in the US and orphan-drug status in Japan and the European Union.
The NMPA gave the green light for commercial sales of a rare-disease therapy for narcolepsy type 1 in people aged 16 and older, state media reported.
The drug was not named, but reports said it had won fast-track designations in the US and orphan-drug designation in Japan and the European Union. Orphan-drug status means a therapy for a rare disease gets government incentives like tax breaks and exclusive rights to make development viable.
Narcolepsy type 1 is a lifelong brain condition that makes people intensely sleepy during the day and causes them to fall asleep without warning. For many sufferers, it also causes them to suddenly lose control of their muscles when they feel strong emotions, like laughing, being surprised, or getting angry.
Offene Fragen
- What is the name of the approved drug?
- Which company manufactures this drug?
